34 patents
Utility
Chimeric antigen receptors targeting TIM-1
3 Jan 23
The invention provides chimeric antigen receptors (CARs) that specifically bind to the T-cell immunoglobulin and mucin domain 1 (TIM-1) protein.
Terrance A. Stadheim, Joana M. Murad, Jake Reder, Henry C. Marsh, Jr., Li-Zhen He, Tibor Keler
Filed: 12 Jan 18
Utility
ANTI-CD27 and ANTI-PD-L1 Antibodies and Bispecific Constructs
13 Oct 22
Provided herein are anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain.
Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE
Filed: 14 Apr 22
Utility
Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
4 Oct 22
Provided herein are anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain.
Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He
Filed: 17 Apr 19
Utility
Antibodies That Bind Human CD27 and Uses Thereof
21 Jul 22
Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed.
Tibor KELER, Henry C. MARSH, Lizhen HE, Laura A. VITALE, Lawrence J. THOMAS
Filed: 22 Oct 21
Utility
Anti-axl Antibodies and Methods of Use Thereof
9 Jun 22
Provided herein are compositions, methods and uses involving antibodies that specifically bind to Axl, a receptor tyrosine kinase.
Tibor Keler, Diego Alvarado, Richard W. Gedrich, Joel Goldstein, Laura Vitale, Thomas O'Neill, Andrea Crocker, Jenifer Widger, Michael B. Murphy, Shannon Pankratz
Filed: 27 Mar 20
Utility
Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
17 May 22
Provided herein are anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain.
Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He
Filed: 18 Aug 21
Utility
Treatment of Eosinophil or Mast Cell Related Disorders
24 Feb 22
Provided herein are methods and uses involving antibodies that specifically bind to a KIT receptor tyrosine kinase for managing, treating, or preventing an eosinophil or mast cell related disorder and/or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).
Theresa Marie LaVallee, Gerald McMahon
Filed: 4 Aug 20
Utility
ANTI-CD27 and ANTI-PD-L1 Antibodies and Bispecific Constructs
27 Jan 22
Provided herein are novel anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain.
Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE
Filed: 18 Aug 21
Utility
Methods of Using CD27 Antibodies As Conditioning Treatment for Adoptive Cell Therapy
20 Jan 22
Methods of performing adoptive immunotherapy comprising administering to patients a CD27 antibody in combination with an adoptive immunotherapy (e.g., genetically modified autogenous and allogenous T-cells) are provided.
Lizhen HE, Tibor KELER, Anna WASIUK
Filed: 10 Dec 19
Utility
Anti-kit Antibodies and Uses Thereof
13 Jan 22
Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies.
Yaron Hadari, Elizabeth M Mandel-Bausch, Francis Joseph Carr, Timothy David Jones, Laura Clare Alexandra Perry
Filed: 4 Aug 20
Utility
Antibodies that bind human CD27 and uses thereof
23 Nov 21
Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed.
Tibor Keler, Henry C. Marsh, Lizhen He, Laura A. Vitale, Lawrence J. Thomas
Filed: 2 Jul 15
Utility
Anti-ALK antibodies and methods for use thereof
17 Aug 21
Provided herein are compositions, methods and uses involving antibodies that specifically bind to ALK, a receptor tyrosine kinase, and modulate the expression and/or activity of ALK.
Diego Alvarado, Jay Lillquist, Gwenda Ligon, Michael Feldhaus
Filed: 26 Aug 16
Utility
ANTI-CD27 and ANTI-PD-L1 Antibodies and Bispecific Constructs
1 Jul 21
Provided herein are novel anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain.
Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE
Filed: 17 Apr 19
Utility
Agonistic Antibodies That Bind CD40
20 May 21
Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed.
Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer WIDGER
Filed: 8 Jan 21
Utility
Use of ANTI-PD-1 Antibody In Combination with ANTI-CD27 Antibody In Cancer Treatment
13 May 21
This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody.
Vladimir CORIC, Tibor KELER, Thomas DAVIS
Filed: 16 Nov 20
Utility
Anti-MET Antibodies and Methods of Use Thereof
6 May 21
Provided herein are compositions, methods and uses involving antibodies that specifically bind to MET, a receptor tyrosine kinase, and modulate the expression and/or activity of MET.
Yan Yang, Sreekala Mandiyan, Brett Robinson, Lida Kimmel, Yaron Hadari, Timothy David Jones, Francis Joseph Carr, Robert George Edward Holgate, Richard Weldon
Filed: 15 Sep 20
Utility
Methods of Treating Cancer with Dendritic Cell Mobilizing Agents
18 Mar 21
Methods of treating cancer comprising administering to patients a dendritic cell mobilizing agent (e.g., Flt3 ligand) in combination with radiation and/or immunoregulatory agents (e.g., checkpoint inhibitors), are disclosed.
Tibor KELER, Michael YELLIN, Chandan GUHA, Nitin OHRI
Filed: 25 Jan 19
Utility
Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies
9 Mar 21
Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed.
Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He, Tom O'Neill, Andrea Crocker, Karuna Sundarapandiyan, Lawrence J. Thomas, Jenifer Widger
Filed: 6 Aug 20
Utility
Nucleic acids encoding agonistic antibodies that bind CD40
14 Dec 20
Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed.
Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He, Tom O'Neill, Andrea Crocker, Karuna Sundarapandiyan, Lawrence J. Thomas, Jenifer Widger
Filed: 17 Apr 17
Utility
Anti-kit Antibodies and Uses Thereof
9 Dec 20
Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies.
Yaron Hadari, Elizabeth M. Mandel-Bausch, Susanne Radke, Joseph Schlessinger, Yoshihisa Suzuki
Filed: 13 Aug 20